BB BIOTECH AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.3 EUR | -0.23% |
|
+4.97% | -4.84% |
| Apr. 27 | Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022. | CI |
| Apr. 26 | Switzerland's BB Biotech Swings to Q1 Profit; Operating Income Jumps | MT |
| Sales 2024 * | 249M 277M 255M | Sales 2025 * | 268M 299M 275M | Capitalization | 2.33B 2.59B 2.38B |
|---|---|---|---|---|---|
| Net income 2024 * | 213M 237M 218M | Net income 2025 * | 166M 185M 170M | EV / Sales 2024 * | 10.5 x |
| Net Debt 2024 * | 301M 335M 308M | Net Debt 2025 * | 333M 371M 341M | EV / Sales 2025 * | 9.9 x |
| P/E ratio 2024 * |
11
x | P/E ratio 2025 * |
10
x | Employees | 10 |
| Yield 2024 * |
5.21% | Yield 2025 * |
5.31% | Free-Float | 97.24% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.23% | ||
| 1 week | +4.97% | ||
| Current month | +4.09% | ||
| 1 month | +3.71% | ||
| 3 months | -1.48% | ||
| 6 months | -8.46% | ||
| Current year | -4.84% |
1 week
40.90
43.60
1 month
40.1043.60
Current year
39.9552.60
1 year
37.0052.60
3 years
37.0085.40
5 years
37.0086.40
10 years
24.7886.40
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Koller
CIO | Chief Investment Officer | 54 | 03-12-31 |
| - | - | ||
| - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Clive Meanwell
BRD | Director/Board Member | 67 | 03-12-31 |
| Director/Board Member | 63 | 19-12-31 | |
| Chairman | 63 | 19-03-20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-12 | 43.3 | -0.23% | 18,247 |
| 24-07-11 | 43.4 | +2.84% | 22,918 |
| 24-07-10 | 42.2 | +0.72% | 18,274 |
| 24-07-09 | 41.9 | +2.44% | 17,945 |
| 24-07-08 | 40.9 | -0.85% | 9,127 |
Delayed Quote Xetra, July 12, 2024 at 11:35 am EDT
More quotes
BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Companyâs portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
Calendar
2024-07-26
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
42.4
CHF
Average target price
47.7
CHF
Spread / Average Target
+12.50%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +22.10% | 46.55B | |
| +46.45% | 41.84B | |
| -3.12% | 40.84B | |
| +36.10% | 32.95B | |
| -6.30% | 28.27B | |
| +18.71% | 27.78B | |
| +46.15% | 14.26B | |
| +44.52% | 13.69B | |
| +0.19% | 12.18B |
- Stock Market
- Equities
- BION Stock
- BBZA Stock
